Biokine
1 known investors
Biokine Therapeutics is a private biopharmaceutical company developing cancer therapeutics targeting tumor migration, survival, and immune-response pathways; its lead product BKT140/BL8040 is a CXCR4 receptor inhibitor used for stem cell mobilization and cancer immunotherapy. The company has also built the MigHit and ImmunHit phenotypic screening platforms to identify small molecules targeting migration/survival pathways and IFN-g mediated immune responses in cancer and inflammation.
BiotechHealthtech